InterVenn innovates cancer diagnostics using artificial intelligence

KUALA LUMPUR: InterVenn Biosciences has announced its capability to correctly predict samples from patients with nasopharyngeal cancer with a 100 per cent accuracy.

The study, involving 100 samples, was carried out in collaboration with the Institute for Medical Research, under the Health Ministry’s National Institutes of Health. It was facilitated by Clinical Research Malaysia, an agency under the ministry.

The samples were studied by InterVenn using its proprietary approach to analyse glycoproteins using artificial intelligence (AI).

The company, in a statement, said it was in talks with international partners to expedite the commercialisation and clinical validation of a new diagnostics for nasal cancer and other indications.

Glycoproteins remain the most commonly used form of bloodbased markers for cancer. This is because most blood-based cancer biomarkers lack sensitivity when used for screening.

Glycoproteomics technology, coupled with AI, allows panels of novel glycoprotein markers that correspond to cancers to be identified.

The approach used in this analysis is similar to the company’s liquid biopsy to investigate a clinical decision-making tool for ovarian cancer, aimed at distinguish malignant pelvic tumours from benign ones.

Intervenn Biosciences, which has offices in the United States, Malaysia and the Philippines, is changing the way the world deals with cancer and other diseases by combining mass spectrometry and AI to unlock glycoproteomics for biomarker and target discovery.

For more details, visit https://intervenn.bio. Bernama